search
Back to results

Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age

Primary Purpose

Infertility

Status
Suspended
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Preimplantation Genetic Diagnosis (PGD)
Sponsored by
Reprogenetics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Infertility focused on measuring aneuploidy, miscarriage, pregnancy loss, PGD, PGS, Preimplantation Genetic Diagnosis, chromosome abnormalities, IVF, ART

Eligibility Criteria

37 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Premenopausal infertile women wishing to conceive
  • Aged 37 42 years, inclusive,
  • Regular menstrual cycles (generally 25 35 days in length) and screening early follicular phase FSH within normal limits.

Exclusion Criteria:

  • Clinically significant systemic disease;
  • Any contraindication to pregnancy or carrying pregnancy to term;
  • Known ASRM Grade III or IV endometriosis;
  • Clinically significant abnormal findings on a transvaginal ultrasound within 6 weeks prior to the beginning of OCP treatment;
  • Extrauterine pregnancy within 3 months prior to the beginning of OCP treatment;
  • ≥ 3 prior, initiated, consecutive ART cycles without a clinical pregnancy;
  • Prior severe OHSS;
  • TESA and TESE patients;
  • Patients carriers of chromosomal or genetic diseases.
  • Egg donation cycles.
  • Frozen Cycles.

Sites / Locations

  • ART Reproductive Center,
  • Fertility Centers of Illinois
  • Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center
  • Reprogenetics
  • IVI Barcelona

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

1

2

Arm Description

Control: assisted hatching, without Preimplantation Genetic Diagnosis

Test: embryo biopsy with Preimplantation Genetic Diagnosis

Outcomes

Primary Outcome Measures

ongoing pregnancy rate (past 2nd trimester).

Secondary Outcome Measures

spontaneous abortions
pregnancy
implantation

Full Information

First Posted
March 26, 2008
Last Updated
February 21, 2010
Sponsor
Reprogenetics
search

1. Study Identification

Unique Protocol Identification Number
NCT00646893
Brief Title
Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age
Official Title
Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART
Study Type
Interventional

2. Study Status

Record Verification Date
February 2010
Overall Recruitment Status
Suspended
Why Stopped
lack of appropriate funding
Study Start Date
June 2008 (undefined)
Primary Completion Date
January 2011 (Anticipated)
Study Completion Date
April 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Reprogenetics

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to demonstrate that Preimplantation Genetic diagnosis will significantly reduce spontaneous abortions and increase ongoing pregnancy rates in patients of advanced maternal age (37-42) undergoing IVF. We would like to test this hypothesis by a randomized trial performed with the most suitable conditions using very successful IVF laboratories capable to perform the embryo biopsy under strict controlled conditions after proper training and validation of the techniques.
Detailed Description
Indications: Patients of advanced reproductive age wishing to receive preimplantation genetic screening in ART. Objectives: To demonstrate that Preimplantation Genetic diagnosis (PGD) will significantly reduce spontaneous abortions and increase ongoing pregnancy rates in patients of advanced maternal age (37-42) undergoing IVF. Test Method: Preimplantation Genetic Screening through FISH Treatment: In Vitro Fertilization treatment. The resulting embryos of the test group will undergo embryo biopsy followed by PGD with FISH using a 10-probe test with "no result rescue". Study Population: 978 infertile women undergoing ART Major Inclusions: Premenopausal infertile women wishing to conceive, aged 37 42 years, inclusive, regular menstrual cycles and screening early follicular phase FSH within normal limits. Major Exclusions: Clinically significant systemic disease; any contraindication to pregnancy or carrying pregnancy to term; known ASRM Grade III or IV endometriosis; clinically significant abnormal findings on a transvaginal ultrasound within 6 weeks prior to the beginning of OCP treatment; extrauterine pregnancy within 3 months prior to the beginning of OCP treatment; poor response in a previous ART cycle (≤ 3 oocytes retrieved); ≥ 3 prior, initiated, consecutive ART cycles without a clinical pregnancy; prior severe OHSS; TESA and TESE patients; patients carriers of chromosomal or genetic diseases. Randomization: Eligible patients will be randomized in a 1:1 ratio to either: Group A: Hatching "or" Group B: Hatching + PGS Study Procedures The study will be conducted on an outpatient basis. All pre-study screening assessments will be performed prior to treatment start. Post-treatment Oocyte retrieval and embryology procedures will be Procedures performed according to the usual practice of the study center. Test Method Hatching, embryo biopsy, fixation and Fluorescence in-situ Hybridization (FISH) will be performed strictly in line with the methodology included in this protocol and only carried out by technicians certified by Reprogenetics. Primary Endpoint: ongoing pregnancy rate (past 2nd trimester). Secondary Endpoints: implantation rate, pregnancy rate, miscarriage rate and live birth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
aneuploidy, miscarriage, pregnancy loss, PGD, PGS, Preimplantation Genetic Diagnosis, chromosome abnormalities, IVF, ART

7. Study Design

Primary Purpose
Screening
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
No Intervention
Arm Description
Control: assisted hatching, without Preimplantation Genetic Diagnosis
Arm Title
2
Arm Type
Experimental
Arm Description
Test: embryo biopsy with Preimplantation Genetic Diagnosis
Intervention Type
Procedure
Intervention Name(s)
Preimplantation Genetic Diagnosis (PGD)
Other Intervention Name(s)
PGS, Preimplantation Genetic Screening
Intervention Description
one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by "no result rescue" (Colls et al. 2007)
Primary Outcome Measure Information:
Title
ongoing pregnancy rate (past 2nd trimester).
Time Frame
after 21 days, 20 weeks, and 7 month of treatment
Secondary Outcome Measure Information:
Title
spontaneous abortions
Time Frame
within 1st and 2nd trimester
Title
pregnancy
Time Frame
one month for presence of fetal sac
Title
implantation
Time Frame
first month, for presence of fetal sacs

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
37 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Premenopausal infertile women wishing to conceive Aged 37 42 years, inclusive, Regular menstrual cycles (generally 25 35 days in length) and screening early follicular phase FSH within normal limits. Exclusion Criteria: Clinically significant systemic disease; Any contraindication to pregnancy or carrying pregnancy to term; Known ASRM Grade III or IV endometriosis; Clinically significant abnormal findings on a transvaginal ultrasound within 6 weeks prior to the beginning of OCP treatment; Extrauterine pregnancy within 3 months prior to the beginning of OCP treatment; ≥ 3 prior, initiated, consecutive ART cycles without a clinical pregnancy; Prior severe OHSS; TESA and TESE patients; Patients carriers of chromosomal or genetic diseases. Egg donation cycles. Frozen Cycles.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Santiago Munne, PhD
Organizational Affiliation
Reprogenetics
Official's Role
Principal Investigator
Facility Information:
Facility Name
ART Reproductive Center,
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90210
Country
United States
Facility Name
Fertility Centers of Illinois
City
Highland Park
State/Province
Illinois
ZIP/Postal Code
60035
Country
United States
Facility Name
Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center
City
Livingston
State/Province
New Jersey
ZIP/Postal Code
07039
Country
United States
Facility Name
Reprogenetics
City
Livingston
State/Province
New Jersey
ZIP/Postal Code
07039
Country
United States
Facility Name
IVI Barcelona
City
Barcelona
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
17296179
Citation
Colls P, Escudero T, Cekleniak N, Sadowy S, Cohen J, Munne S. Increased efficiency of preimplantation genetic diagnosis for infertility using "no result rescue". Fertil Steril. 2007 Jul;88(1):53-61. doi: 10.1016/j.fertnstert.2006.11.099. Epub 2007 Feb 12.
Results Reference
background

Learn more about this trial

Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age

We'll reach out to this number within 24 hrs